The clinical trial result of HLB’s targeted anticancer medicine rivoceranib will be presented at the 2022 International Association for the Study of Lung Cancer (IASLC 2022), the company said Thursday.
IASLC, the world’s largest symposium for lung cancer and other thoracic malignancy, will be held in Vienna from Aug. 6-9
Currently, platinum cytotoxic drug combined with immune checkpoint inhibitor receives the spotlight as the treatment for non-small cell lung cancer (NSCLC). However, the adverse effect of cytotoxic treatment is relatively high, causing researchers to conduct studies for an alternative treatment.
Against this backdrop, the interim result of phase 2 clinical trial of the combination treatment of rivoceranib (VEGFR-2 inhibitor), camrelizumab (PD-1 inhibitor), and albumin-binding paclitaxel on 63 EGFR and ALK-negative lung cancer patients at a cancer hospital in Hunan, China, is drawing attention, HBL said.
According to the study abstract unveiled on Tuesday, the first validity indicator of mPFS was 10.97 months, and the second validity indicator of objective response rate (ORR) and disease control rate (DCR) showed high levels of 71.1 percent and 97.4 percent, respectively.
That seems to be because rivoceranib showed excellence when used jointly with other anticancer medicines by increasing the reaction rate of immuno-oncology and permeation of cancer cells of immunologically competent cells.
As if to back such an outcome, various results of combined clinical trials of rivoceranib have been announced at global conferences and scientific journals. In addition, the high effect of combined clinical trials on pulmonary cancer has also been announced at the IASLC every year.
For instance, in a previous conference, a clinical trial of rivoceranib combined with pyrotinib on 14 HER2-positive patients showed a disease control rate of 100 percent. Pyrotinib is a breast cancer treatment already released to the Chinese market. HBL licensed in pyrotinib from China’s Hangseo Pharmaceutical in 2020, and phase 3 clinical trials are underway in 13 countries as NSCLC treatment, including Korea, China, and the U.S.
“They are preparing to apply for a new drug approval for rivoceranib by proving its efficacy on liver cancer and adenocystic carcinoma through a global clinical trial,” an industry executive said. “Expectations are high on the performance of anticancer drugs whose domestic sales rights are held by HLB, such as rivoceranib and pyrotinib.”